Many studies have focused on the predictive biomarkers for the response of PD-L1 inhibitor, such as tumor mutational burden (TMB), PD-1 expression and Combined Positive Score (CPS) [46, 47]. This evidence concerns the gene PDCD1 and neoplasm.